HOME >> BIOLOGY >> NEWS
Macrochem acquires option to license pexiganan

WELLESLEY HILLS, Mass., July 10 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTCBB: MACM - News) today announced that it has signed an exclusive option to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for topical treatment of patients with mild diabetic foot infection (DFI), from Genaera Corporation (Genaera).

"We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase 3 clinical trials. It also fits our strategic focus and complements our lead product candidate, EcoNail(TM) for treatment of nail fungus currently in a fully enrolled Phase 2 trial and progressing on track with an interim assessment of clinical data later this year after all patients have been treated for twenty four weeks," said Robert J. DeLuccia, President and CEO of MacroChem.

Clinical trials with pexiganan previously conducted by Genaera include two Phase 3 trials submitted in a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 1998. At that time, outstanding issues with CMC (Chemistry, Manufacturing and Controls) and an FDA request for one additional controlled trial precluded approval.

Mr. DeLuccia further noted, "We would be pleased to have pexiganan in our hands since we believe that, if approved, it would be welcomed by physicians and patients for the treatment of diabetic foot infection. In recent years, there have been many advances in the manufacturing of peptides, a better understanding of the treatment of diabetic foot infection, improvements in clinical trial design and execution, and more clarity concerning regulatory requirements for topical anti-infectives with the potential market being even more attractive than before."

He added, "There continues to be a very large and growing incidence of diabetes and, as a result, a growing number of diabetic foot infections in the
'"/>

Contact: Bill Douglass
bdouglass@investorrelationsgroup.com
212-825-3210
MacroChem
10-Jul-2007


Page: 1 2

Related biology news :

1. Biogen Idec acquires Brandeis spin-out
2. Wiley acquires publications from Carpe Diem Communications
3. Ossur hf. acquires the Gibaud Group in France
4. Springer acquires BioTribune Magazine and Biotribune.com
5. Stevens Davidson Laboratory acquires new research vessel
6. Accentia Biopharmaceuticals acquires exclusive license
7. Ossur acquires US orthotics company Royce Medical
8. Molecular Profiling Institute, Inc. acquires NanoBiomics, Inc.
9. European approval of HIV drug darunavir will provide a potent new option with Fuzeon
10. Fat stem cells being studied as option for breast reconstruction
11. Drug offers new options for leukemia patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/1/2016)... YORK , Feb. 1, 2016  Today, the ... Association (AHA) announced plans to develop a first of ... computing power of IBM Watson. In the first application ... AHA, IBM (NYSE: IBM ), and Welltok will ... and health assessments with cognitive analytics, delivered on Welltok,s ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... John F. Kennedy (JFK) International Airport, New York City ... (CBP) identify imposters attempting to enter the United States ... to them. pilot testing of the system at ... three terminals at JFK during January 2016. --> pilot ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove ... for the National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts ... are heard throughout the drug regulatory review process. , “Adding Diane Dorman is ...
(Date:2/9/2016)... Feb. 9, 2016 BERG, a biopharmaceutical ... research approach, has announced the appointment of ... Chief Operating Officer. Haddock brings to BERG over ... 12 years in senior financial functions at pharmaceutical ... business organizational management. Niven R. ...
(Date:2/8/2016)... 2016 --> ... innovation-driven oncology company developing next generation cancer therapeutics ... announced that chairman emeritus of Tata Sons Limited, ... company as part of the first close of ... Navam Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ...
(Date:2/8/2016)... ... ... Bulk food product inspection systems are specifically designed to ... production process. Despite frequently inspecting loose product prior to packaging, product inspection systems ... of dry powders. , Mettler-Toledo Product Inspection's brand-new white paper entitled "Improving Food ...
Breaking Biology Technology:
Cached News: